Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Neoantigen Cancer Vaccine Market Outlook

The global neoantigen cancer vaccine market size was valued at USD 116.74 million in 2023, driven by the rising investments in the research and development of the immunotherapy and rapid technological advancements in the healthcare sector. The market size is anticipated to grow at a CAGR of 69.43% during the forecast period of 2024-2032 to achieve a value of USD 13,431.43 million by 2032.

Neoantigen Cancer Vaccine: Introduction

Neoantigens are tumour-specific antigens produced in cancer cells that signify the changes which happen throughout the transformative process. These substances are truly unique to cancer tissue and have the potential to be identified by the immune system, resulting in the host's distinct anti-tumour activity. Neoantigens are peptides that are abnormally expressed as a result of genome alterations and are translated to form live peptides. They function as mechanisms for the immune system to distinguish between own and tumour tissue and have been identified as a novel target for cancer immunotherapies.

Global Neoantigen Cancer Vaccine Market Analysis

There are several key trends propelling the growth of the market size. The introduction of immunotherapy has emerged as a groundbreaking approach in cancer treatment and neoantigen cancer vaccines as a form of immunotherapy that specifically target neoantigens, which are tumour-specific antigens derived from genetic mutations has proven to be transformative in the approach to treat cancer. The increasing understanding of the immune system and its role in fighting cancer has fuelled the neoantigen cancer vaccines market demand further. The interest in neoantigen cancer vaccines has also spurred a significant increase in research and clinical trials which further has caused global neoantigen cancer vaccine market to witness dynamic growth.

Global Neoantigen Cancer Vaccine Market Segmentations

Based on segments, the market is divided into product type, neoantigen type, route of administration, cell, technology, delivery mechanism, applications, and region.

Market Breakup by Product Type

  • Personalized Neoantigen Vaccine 
  • Off-the Shelf Neoantigen Vaccine

Market Breakup by Neoantigen Type

  • Synthetic Long Peptide (SLP)
  • Dendritic Cell
  • Nucleic Acid
  • Tumour Cell

Market Breakup by Route of Administration

  • Intravenous
  • Intramuscular
  • Transdermal
  • Others

Market Breakup by Cell

  • Autologous
  • Allogenic

Market Breakup by Technology

  • RNA Sequencing
  • Whole Genome Sequencing
  • HLA Typing
  • Others

Market Breakup by Delivery Mechanism

  • Liposomes
  • Virosomes
  • Electroporation
  • Gene Gun
  • Others

Market Breakup by Applications

  • Lung, Melanoma
  • Gastrointestinal
  • Brain Cancer
  • Others

Market Breakup by Region

  • North America 
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Neoantigen Cancer Vaccine Market Scenario

The market has a lot of room to expand since immunotherapeutic treatment research and development is still ongoing, both in terms of understanding their mechanism of action, clinical relevance, and usability. The research and clinical trials in the field of immunotherapy is receiving enormous amounts of financial support from pharmaceutical corporations, biotech businesses, and academic institutions which has led to further growth capabilities for global neoantigen cancer vaccine market.

Global Neoantigen Cancer Vaccine Market: Competitor Landscape

The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model, along with giving a SWOT analysis. The report gives a detailed analysis of the following neoantigen cancer vaccine companies, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • OSE Immunotherapeutics SA
  • Gritstone bio, Inc.
  • BioNTech SE
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Moderna Inc.
  • Avidea Technologies, Inc.
  • Eli Lilly and Company
  • Vaccibody AS
  • Agenus Inc.
  • Novogene Co., Ltd.
  • ZIOPHARM Oncology Inc.
  • ISA Pharmaceuticals B.V.
  • BrightPath Biotherapeutics Co., Ltd.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product Type
  • Neoantigen Type
  • Route of Administration
  • Cell
  • Technology
  • Delivery Mechanism
  • Applications
  • Region
Breakup by Product Type
  • Personalized Neoantigen Vaccine 
  • Off-the Shelf Neoantigen Vaccine
Breakup by Neoantigen Type
  • Synthetic Long Peptide (SLP)
  • Dendritic Cell
  • Nucleic Acid
  • Tumour Cell
Breakup by Route of Administration
  • Intravenous
  • Intramuscular
  • Transdermal
  • Others
Breakup by Cell
  • Autologous
  • Allogenic
Breakup by Technology
  • RNA Sequencing
  • Whole Genome Sequencing
  • HLA Typing
  • Others
Breakup by Delivery Mechanism
  • Liposomes
  • Virosomes
  • Electroporation
  • Gene Gun
  • Others
Breakup by Applications
  • Lung, Melanoma
  • Gastrointestinal
  • Brain Cancer
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • OSE Immunotherapeutics SA
  • Gritstone bio, Inc.
  • BioNTech SE
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Moderna Inc.
  • Avidea Technologies, Inc.
  • Eli Lilly and Company
  • Vaccibody AS
  • Agenus Inc.
  • Novogene Co., Ltd.
  • ZIOPHARM Oncology Inc.
  • ISA Pharmaceuticals B.V.
  • BrightPath Biotherapeutics Co., Ltd.

Neoantigen Cancer Vaccine Market Report Snapshots

Neoantigen Cancer Vaccine Market Size

Neoantigen Cancer Vaccine Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Key Questions Answered in the Report

The market attained a value of USD 116.74 million in 2023.

The market size is anticipated to grow at a CAGR of 69.43% during the forecast period of 2024-2032 to attain a value of around USD 13,431.43 million in 2032.

The growth of the market is driven by factors like rising investments in the research and development of the immunotherapy and rapid technological advancements in the healthcare sector.

The introduction of immunotherapy has emerged as a groundbreaking approach in cancer treatment and neoantigen cancer vaccines as a form of immunotherapy that specifically target neoantigens, which are tumour-specific antigens derived from genetic mutations has proven to be transformative in the approach to treat cancer.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

The different types of products in the market are personalized neoantigen vaccine and off-the shelf neoantigen vaccine.

The neoantigen types include synthetic long peptide (SLP), dendritic cell, nucleic acid, and tumour cell.

The route of administration can be categorised into intravenous, intramuscular, and transdermal, among others.

The cell types can be categorised into autologous and allogenic.

The different delivery mechanism in the market includes liposomes, virosomes, electroporation, and gene gun, among others.

The different technologies used in the market are RNA sequencing, whole genome sequencing, and HLA typing. among other.

The vaccine finds wide applications in the treatment of lung, melanoma, gastrointestinal, and brain cancer, among others.

Key players involved in the market includes OSE Immunotherapeutics SA, Gritstone bio, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co. Inc., Moderna Inc., Avidea Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co., Ltd., and BioNTech SE.

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Pricing Plans

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Strategic Solutions for Informed Decision-Making

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-120-433-0800

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124